BioRestorative Therapies submitted an Investigational New Drug Application to the FDA.
Here are five insights:
1. The company hopes to receive clearance to test its cell therapy drug in a clinical trial.
2. The therapy, BRTX-100, is intended to treat chronic lower back pain caused by degenerative disc disease.
3. BRTX-100 includes autologous cultured mesenchymal stem cells from a patient's bone marrow.
4. The product is designed for a non-surgical, intradiscal procedure performed in a physician's office.